What is Biomerica's market cap?

Biomerica (BMRA) has a market capitalization of $5.0M and trades on NASDAQ.

Who are Biomerica's competitors?

Biomerica's key competitors include Abbott Laboratories, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc.Class A, and others. These companies compete in similar markets and product categories.

What subsidiaries does Biomerica have?

Biomerica's subsidiaries include Biomerica de Mexico, BioEurope GmbH.

Where is Biomerica headquartered?

Biomerica is headquartered in United States of America and employs approximately 62 people. It has been publicly traded since 1978.

Biomerica

BMRA

Biomerica is a global biomedical technology company that develops, manufactures, and markets advanced diagnostic and therapeutic products for clinical laboratories and point-of-care settings.

Market cap

$5.01M-44.1%

Table of contents

Earnings

Q1 2026 report

April 13, 2026

Revenue$1.1MMiss by $2.5M EPS-$0.44Beat by $0.76

Read the full report

Next report

Aug 27, 2026 (In 4 weeks)

Revenue estimate$3.6M

EPS estimate-$1.20

Competitors

By market cap

Abbott$182.00B-17.2%

Quest Diagnostics$25.6B+36.3%

Revvity$12.1B+7.6%

Bio-Rad Laboratories$8.5B+22.9%

Neogen$2.0B+72.8%

QuidelOrtho Corporation$1.1B-35.0%

Biomerica$5.0M-47.7%

ONC

Onconetix, Inc.$3.0M+55.2%

By revenue growth

Quest Diagnostics+9.9%

Abbott+8.1%

Revvity+4.8%

Bio-Rad Laboratories+1.9%

QuidelOrtho Corporation-3.9%

Neogen-3.9%

By net margin

Abbott11.65%-20.8pp

Quest Diagnostics9.19%+0.2pp

Revvity8.26%-2.1pp

Bio-Rad Laboratories6.52%+91.7pp

QuidelOrtho Corporation-45.57%-32.6pp

Neogen-69.94%-16.4pp

Profile

Biomerica is a global biomedical technology company that develops, manufactures, and markets advanced diagnostic and therapeutic products for clinical laboratories and point-of-care settings. The company specializes in patented diagnostic-guided therapy (DGT) and rapid test kits that analyze blood, urine, and other specimens to manage chronic inflammatory diseases and gastrointestinal conditions. Its core value proposition focuses on providing accurate, instrumentation-free diagnostic tools that reduce healthcare costs through early detection and personalized dietary management.

Competitive position

Biomerica leverages a strong patent portfolio in diagnostic-guided therapy and rapid point-of-care testing to compete against much larger medical and pharmaceutical entities.

GeographiesUnited States, Mexico, Europe, Asia, Middle East

Customer segmentsHealthcare Providers, Diagnostic Laboratories, Retail Consumers, Pharmaceutical Companies

Business modelManufacturing, Licensing, Diagnostic-Guided Therapy (DGT)

SuppliersAntibody and antigen suppliers, Commodity plastic vendors, Chemical and reagent suppliers, Packaging material providers

CustomersIndependent medical distributors, Gastroenterology physician groups, Clinical and research institutions, Retail pharmacy chains

CountryUnited States of America

Listed1978

Employees62.0

CEOZackary S. Irani

SectorHealthcare

IndustryMedical - Devices

Websitebiomerica.com

FilingsSEC EDGAR

Questions, answered.

What is Biomerica's market cap?: Biomerica (BMRA) has a market capitalization of $5.0M and trades on NASDAQ.
Who are Biomerica's competitors?: Biomerica's key competitors include Abbott Laboratories, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc.Class A, and others. These companies compete in similar markets and product categories.
What subsidiaries does Biomerica have?: Biomerica's subsidiaries include Biomerica de Mexico, BioEurope GmbH.
Where is Biomerica headquartered?: Biomerica is headquartered in United States of America and employs approximately 62 people. It has been publicly traded since 1978.